Drug Profile
Bosutinib - Pfizer
Alternative Names: Bosulif; Bosutinib monohydrate - Pfizer; PF-05208763; PF-5208763; SKI-606Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Aniline compounds; Antineoplastics; Chlorine compounds; Nitriles; Piperazines; Quinolines; Small molecules; Urologics
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia
- Phase II Glioblastoma
- Phase I/II Amyotrophic lateral sclerosis; Precursor cell lymphoblastic leukaemia-lymphoma
- Discontinued Autosomal dominant polycystic kidney disease; Breast cancer; Solid tumours
Most Recent Events
- 25 Mar 2024 Launched for Chronic myeloid leukaemia (First-line therapy) in South Korea (PO) (NCT06297161)
- 25 Mar 2024 Launched for Chronic myeloid leukaemia (Second-line therapy or greater) in South Korea (PO) (NCT06297161)
- 03 Oct 2023 Chemical structure information added for the salt form of the drug